Global /China /Healthcare /Biotechnology /300683
chevron_leftBack
Wuhan Hiteck Biological Pharma Co.,Ltd logo

Wuhan Hiteck Biological Pharma Co.,Ltd

300683
SHE: 300683 Delayed
35.34CNY 0.3%
5.22 USD
As of 14 June 2026, Wuhan Hiteck Biological Pharma Co.,Ltd has a market cap of $680.94M USD, ranking #13108 globally and #3946 in China. It ranks #1185 in the Healthcare sector, and #222 in the Biotechnology industry.
Global Rank
13108
Country Rank
3946
Sector Rank
1185
Industry Rank
222
Key Stats
Market Cap
$680.94MUSD
4.61B CNY
Enterprise Value
$628.63MUSD
4.25B CNY
Revenue (TTM)
$80.26MUSD
543.82M CNY
EBITDA (TTM)
-$4.22MUSD
-28.54M CNY
Net Income (TTM)
-$35.48MUSD
-240.38M CNY
EBITDA Margin
-5.2%
Profit Margin
-44%
PS Ratio
8.5
PB Ratio
2.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Ya Chen open_in_new
Employees
1,309
Founded
1992
Website
hiteck.com.cn open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.3% 6.5% -9.2% 13% 9.5% 60%

News

Loading...

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300683
武汉海特生物制药股份有限公司 Class A
ISIN: CNE1000034C5
Shares Out.:
130.894M1 Shares Float: 127.199M2
TV:
SA:
YF:
GF:
BA:
MS:
35.34 CNY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for α –Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs, and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.

Similar Companies

Industry: Biotechnology (China)
Name
Market Cap diff.
PE
$17.44B
136.71B HKD
2K%
25.3
$12.2B
95.58B HKD
2K%
22.1
$8.0B
54.23B CNY
1K%
34.4
$7.33B
49.69B CNY
977%
-
1530
$7.08B
55.5B HKD
940%
5.8
$6.72B
45.52B CNY
887%
61.6
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
AMGN
$182.42B
27K%
23.9
GILD
$159.92B
23K%
19.0
ARGX
$47.84B
41.39B EUR
7K%
39.9
$44.84B
68.19T KRW
6K%
35.5
CSL
$42.36B
60.27B AUD
6K%
29.3
LONN
$42.3B
33.71B CHF
6K%
37.2
chevron_leftBack